Review
DOI DOI: 10.62063/rev-22

The predictive value of metabolomic-related biomarkers in breast cancers: Current approaches in biotechnology

Ahishtan Febrian Nishanthan1, Ermira Jahja2, Tamar Peshkova1, Nameera Parveen Shaikh3, Aleena Parveen Shaikh1, Joy Dip Barua4, Irina Nakashidze1
  1. 1 Batumi Shota Rustaveli State University
  2. 2 Western Balkans University
  3. 3 Toronto Metropolitan University
  4. 4 Pondicherry University

Abstract

Breast cancer is the second most common cancer worldwide and is a leading cause of cancer-related mortality in women. The rising burden of breast cancer highlights the need for more accurate, non-invasive, and informative diagnostic tools. Despite the current advancements in medicine, predicting treatment response and patient prognosis remains challenging. It has thus become imperative to address the need for precise and reliable prognostic and diagnostic tools. Metabolic profiles, such as lipid processing and steroid hormone metabolism, have recently emerged as significant biomarkers in tumor biology, especially for early detection, prognosis, and therapy monitoring. This literature review explores the predictive value of serum lipid profiles and selected steroids as biomarkers in breast tumors. It shows their potential in improving diagnostic strategies and treatment planning in breast cancer management. These approaches offer valuable insights into tumor biology, metabolic changes, and hormone-driven pathways. Despite current challenges in sample preparation, data interpretation, and technical demands, recent advances such as high-resolution mass spectrometry, as well as spatial metabolomics and artificial intelligence, are helping to overcome these barriers. With continued research and technological progress, metabolomic-related biomarkers are expected to see broader use in clinical settings, supporting personalized treatment and improving outcomes for breast cancer patients.

How to Cite

Nishanthan, A. F., Jahja, E., Peshkova, T., Shaikh, N. P., Shaikh, A. P., Barua, J. D., & Nakashidze, I. (2026). The predictive value of metabolomic-related biomarkers in breast cancers: Current approaches in biotechnology. EUCHEMBIOJ Reviews, 2(1), e26001. https://doi.org/10.62063/rev-22
Endnote/Zotero/Mendeley (RIS) BibTeX

References

  1. Africander, D., & Storbeck, K.-H. (2018). Steroid metabolism in breast cancer: Where are we and what are we missing? Molecular and Cellular Endocrinology, 466, 86–97. https://doi.org/10.1016/j.mce.2017.05.016
  2. Ahluwalia, K., Ebright, B., Chow, K., Dave, P., Mead, A., Poblete, R., Louie, S. G., & Asante, I. (2022). Lipidomics in Understanding Pathophysiology and Pharmacologic Effects in Inflammatory Diseases: Considerations for Drug Development. Metabolites, 12(4), 333. https://doi.org/10.3390/metabo12040333
  3. Anh, N. H., Long, N. P., Kim, S. J., Min, J. E., Yoon, S. J., Kim, H. M., Yang, E., Hwang, E. S., Park, J. H., Hong, S.-S., & Kwon, S. W. (2019). Steroidomics for the Prevention, Assessment, and Management of Cancers: A Systematic Review and Functional Analysis. Metabolites, 9(10), 199. https://doi.org/10.3390/metabo9100199
  4. Anh, N. K., Thu, N. Q., Tien, N. T. N., Long, N. P., & Nguyen, H. T. (2024). Advancements in Mass Spectrometry-Based Targeted Metabolomics and Lipidomics: Implications for Clinical Research. Molecules, 29(24), 5934. https://doi.org/10.3390/molecules29245934
  5. Babiker, F. (2002). Estrogenic hormone action in the heart: Regulatory network and function. Cardiovascular Research, 53(3), 709–719. https://doi.org/10.1016/S0008-6363(01)00526-0
  6. Bathen, T. F., Geurts, B., Sitter, B., Fjøsne, H. E., Lundgren, S., Buydens, L. M., Gribbestad, I. S., Postma, G., & Giskeødegård, G. F. (2013). Feasibility of MR Metabolomics for Immediate Analysis of Resection Margins during Breast Cancer Surgery. PLoS ONE, 8(4), e61578. https://doi.org/10.1371/journal.pone.0061578
  7. Caceres, S., Peña, L., Silvan, G., Illera, M. J., Woodward, W. A., Reuben, J. M., & Illera, J. C. (2016). Steroid Tumor Environment in Male and Female Mice Model of Canine and Human Inflammatory Breast Cancer. BioMed Research International, 2016, 1–7. https://doi.org/10.1155/2016/8909878
  8. Cao, Y., Xia, B., Zhang, Z., Hu, D., Huang, X., Yuan, J., & Li, F. (2023). Association of Body Fat Distribution and Risk of Breast Cancer in Pre- and Postmenopausal Women. Obesity Facts, 16(4), 356–363. https://doi.org/10.1159/000529834
  9. Capper, C. P., Rae, J. M., & Auchus, R. J. (2016). The Metabolism, Analysis, and Targeting of Steroid Hormones in Breast and Prostate Cancer. Hormones and Cancer, 7(3), 149–164. https://doi.org/10.1007/s12672-016-0259-0
  10. Carmona, A., Mitri, S., James, T. A., & Ubellacker, J. M. (2024). Lipidomics and metabolomics as potential biomarkers for breast cancer progression. Npj Metabolic Health and Disease, 2(1), 24. https://doi.org/10.1038/s44324-024-00027-0
  11. Chen, X., Chen, H., Dai, M., Ai, J., Li, Y., Mahon, B., Dai, S., & Deng, Y. (2016). Plasma lipidomics profiling identified lipid biomarkers in distinguishing early-stage breast cancer from benign lesions. Oncotarget, 7(24), 36622–36631. https://doi.org/10.18632/oncotarget.9124
  12. Chou, F.-J., Liu, Y., Lang, F., & Yang, C. (2021). D-2-Hydroxyglutarate in Glioma Biology. Cells, 10(9), 2345. https://doi.org/10.3390/cells10092345
  13. Clish, C. B. (2015). Metabolomics: An emerging but powerful tool for precision medicine. Molecular Case Studies, 1(1), a000588. https://doi.org/10.1101/mcs.a000588
  14. Colomer, R., González-Farré, B., Ballesteros, A. I., Peg, V., Bermejo, B., Pérez-Mies, B., De La Cruz, S., Rojo, F., Pernas, S., & Palacios, J. (2024). Biomarkers in breast cancer 2024: An updated consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology. Clinical and Translational Oncology, 26(12), 2935–2951. https://doi.org/10.1007/s12094-024-03541-1
  15. Criscitiello, C., & Corti, C. (2022). Breast Cancer Genetics: Diagnostics and Treatment. Genes, 13(9), 1593. https://doi.org/10.3390/genes13091593
  16. Familial breast cancer: Collaborative reanalysis of individual data from 52 epidemiological studies including 58 209 women with breast cancer and 101 986 women without the disease. (2001). The Lancet, 358(9291), 1389–1399. https://doi.org/10.1016/S0140-6736(01)06524-2
  17. Fang, Z., Ren, G., Ke, S., Xu, Q., Chen, Y., Shi, X., Guo, C., & Huang, J. (2025). Serum metabolomic profiling for predicting therapeutic response and toxicity in breast cancer neoadjuvant chemotherapy: A retrospective longitudinal study. Breast Cancer Research, 27(1), 2. https://doi.org/10.1186/s13058-024-01956-w
  18. Freudenheim, J. L. (2020). Alcohol's Effects on Breast Cancer in Women. Alcohol Research: Current Reviews, 40(2), arcr.v40.2.11. https://doi.org/10.35946/arcr.v40.2.11
  19. Fu, Y., Zou, T., Shen, X., Nelson, P. J., Li, J., Wu, C., Yang, J., Zheng, Y., Bruns, C., Zhao, Y., Qin, L., & Dong, Q. (2021). Lipid metabolism in cancer progression and therapeutic strategies. MedComm, 2(1), 27–59. https://doi.org/10.1002/mco2.27
  20. Ghini, V., Laera, L., Fantechi, B., Del Monte, F., Benelli, M., McCartney, A., Tenori, L., Luchinat, C., & Pozzessere, D. (2020). Metabolomics to Assess Response to Immune Checkpoint Inhibitors in Patients with Non-Small-Cell Lung Cancer. Cancers, 12(12), 3574. https://doi.org/10.3390/cancers12123574
  21. Giaquinto, A. N., Sung, H., Miller, K. D., Kramer, J. L., Newman, L. A., Minihan, A., Jemal, A., & Siegel, R. L. (2022). Breast Cancer Statistics, 2022. CA: A Cancer Journal for Clinicians, 72(6), 524–541. https://doi.org/10.3322/caac.21754
  22. Griffin, J. L., & Shockcor, J. P. (2004). Metabolic profiles of cancer cells. Nature Reviews Cancer, 4(7), 551–561. https://doi.org/10.1038/nrc1390
  23. Haddad, T. C., & Goetz, M. P. (2015). Landscape of Neoadjuvant Therapy for Breast Cancer. Annals of Surgical Oncology, 22(5), 1408–1415. https://doi.org/10.1245/s10434-015-4405-7
  24. Hammes, S. R., & Levin, E. R. (2019). Impact of estrogens in males and androgens in females. Journal of Clinical Investigation, 129(5), 1818–1826. https://doi.org/10.1172/JCI125755
  25. He, Z., Chen, Z., Tan, M., Elingarami, S., Liu, Y., Li, T., Deng, Y., He, N., Li, S., Fu, J., & Li, W. (2020). A review on methods for diagnosis of breast cancer cells and tissues. Cell Proliferation, 53(7), e12822. https://doi.org/10.1111/cpr.12822
  26. Hickey, T. E., Robinson, J. L. L., Carroll, J. S., & Tilley, W. D. (2012). Minireview: The Androgen Receptor in Breast Tissues: Growth Inhibitor, Tumor Suppressor, Oncogene? Molecular Endocrinology, 26(8), 1252–1267. https://doi.org/10.1210/me.2012-1107
  27. Hilvo, M., Denkert, C., Lehtinen, L., Müller, B., Brockmöller, S., Seppänen-Laakso, T., Budczies, J., Bucher, E., Yetukuri, L., Castillo, S., Berg, E., Nygren, H., Sysi-Aho, M., Griffin, J. L., Fiehn, O., Loibl, S., Richter-Ehrenstein, C., Radke, C., Hyötyläinen, T., … Orešič, M. (2011). Novel Theranostic Opportunities Offered by Characterization of Altered Membrane Lipid Metabolism in Breast Cancer Progression. Cancer Research, 71(9), 3236–3245. https://doi.org/10.1158/0008-5472.CAN-10-3894
  28. Hong, B. V., Rhodes, C. H., Agus, J. K., Tang, X., Zhu, C., Zheng, J. J., & Zivkovic, A. M. (2023). A single 36-h water-only fast vastly remodels the plasma lipidome. Frontiers in Cardiovascular Medicine, 10, 1251122. https://doi.org/10.3389/fcvm.2023.1251122
  29. Horn, A., & Jaiswal, J. K. (2019). Structural and signaling role of lipids in plasma membrane repair. In Current Topics in Membranes (Vol. 84, pp. 67–98). Elsevier. https://doi.org/10.1016/bs.ctm.2019.07.001
  30. Iacopetta, D., Rechoum, Y., & Fuqua, S. A. W. (2012). The role of androgen receptor in breast cancer. Drug Discovery Today: Disease Mechanisms, 9(1–2), e19–e27. https://doi.org/10.1016/j.ddmec.2012.11.003
  31. Idle, J. R., & Gonzalez, F. J. (2007). Metabolomics. Cell Metabolism, 6(5), 348–351. https://doi.org/10.1016/j.cmet.2007.10.005
  32. Imai, Y., Youn, M., Kondoh, S., Nakamura, T., Kouzmenko, A., Matsumoto, T., Takada, I., Takaoka, K., & Kato, S. (2009). Estrogens Maintain Bone Mass by Regulating Expression of Genes Controlling Function and Life Span in Mature Osteoclasts. Annals of the New York Academy of Sciences, 1173(s1). https://doi.org/10.1111/j.1749-6632.2009.04954.x
  33. Iqbal, M. A., Siddiqui, S., Smith, K., Singh, P., Kumar, B., Chouaib, S., & Chandrasekaran, S. (2023). Metabolic stratification of human breast tumors reveal subtypes of clinical and therapeutic relevance. iScience, 26(10), 108059. https://doi.org/10.1016/j.isci.2023.108059
  34. Irzaldy, A., Gvamichava, R., Beruchashvili, T., Sturua, L., Van Ravesteyn, N. T., De Koning, H. J., & Heijnsdijk, E. A. M. (2024). Breast Cancer Screening in Georgia: Choosing the Most Optimal and Cost-Effective Strategy. Value in Health Regional Issues, 39, 66–73. https://doi.org/10.1016/j.vhri.2023.09.002
  35. Jafari, S. H., Saadatpour, Z., Salmaninejad, A., Momeni, F., Mokhtari, M., Nahand, J. S., Rahmati, M., Mirzaei, H., & Kianmehr, M. (2018). Breast cancer diagnosis: Imaging techniques and biochemical markers. Journal of Cellular Physiology, 233(7), 5200–5213. https://doi.org/10.1002/jcp.26379
  36. Ji, H., Hu, C., Yang, X., Liu, Y., Ji, G., Ge, S., Wang, X., & Wang, M. (2023). Lymph node metastasis in cancer progression: Molecular mechanisms, clinical significance and therapeutic interventions. Signal Transduction and Targeted Therapy, 8(1), 367. https://doi.org/10.1038/s41392-023-01576-4
  37. Johnson, C. H., & Gonzalez, F. J. (2012). Challenges and opportunities of metabolomics. Journal of Cellular Physiology, 227(8), 2975–2981. https://doi.org/10.1002/jcp.24002
  38. Kaaks, R., Berrino, F., Key, T., Rinaldi, S., Dossus, L., Biessy, C., Secreto, G., Amiano, P., Bingham, S., Boeing, H., De Mesquita, H. B. B., Chang-Claude, J., Clavel-Chapelon, F., Fournier, A., Van Gils, C. H., Gonzalez, C. A., Gurrea, A. B., Critselis, E., Khaw, K. T., … Riboli, E. (2005). Serum Sex Steroids in Premenopausal Women and Breast Cancer Risk Within the European Prospective Investigation into Cancer and Nutrition (EPIC). JNCI: Journal of the National Cancer Institute, 97(10), 755–765. https://doi.org/10.1093/jnci/dji132
  39. Kamińska, M., Ciszewski, T., Łopacka-Szatan, K., Miotła, P., & Starosławska, E. (2015). Breast cancer risk factors. Menopausal Review, 3, 196–202. https://doi.org/10.5114/pm.2015.54346
  40. Kanarek, N., Keys, H. R., Cantor, J. R., Lewis, C. A., Chan, S. H., Kunchok, T., Abu-Remaileh, M., Freinkman, E., Schweitzer, L. D., & Sabatini, D. M. (2018). Histidine catabolism is a major determinant of methotrexate sensitivity. Nature, 559(7715), 632–636. https://doi.org/10.1038/s41586-018-0316-7
  41. Kostara, C. E. (2023). Expanding the Molecular Disturbances of Lipoproteins in Cardiometabolic Diseases: Lessons from Lipidomics. Diagnostics, 13(4), 721. https://doi.org/10.3390/diagnostics13040721
  42. Li, X., Li, J., Hu, Q., Zhang, X., & Chen, F. (2024). Association of physical weight statuses defined by body mass index (BMI) with molecular subtypes of premenopausal breast cancer: A systematic review and meta-analysis. Breast Cancer Research and Treatment, 203(3), 429–447. https://doi.org/10.1007/s10549-023-07139-z
  43. Liang, J., Zhang, B., Hu, Y., Na, Z., & Li, D. (2023). Effects of steroid hormones on lipid metabolism in sexual dimorphism: A Mendelian randomization study. Frontiers in Endocrinology, 13, 1119154. https://doi.org/10.3389/fendo.2022.1119154
  44. Lin, C., Tian, Q., Guo, S., Xie, D., Cai, Y., Wang, Z., Chu, H., Qiu, S., Tang, S., & Zhang, A. (2024). Metabolomics for Clinical Biomarker Discovery and Therapeutic Target Identification. Molecules, 29(10), 2198. https://doi.org/10.3390/molecules29102198
  45. Liu, Y., & Cao, X. (2016). Characteristics and Significance of the Pre-metastatic Niche. Cancer Cell, 30(5), 668–681. https://doi.org/10.1016/j.ccell.2016.09.011
  46. McNamara, K. M., Yoda, T., Takagi, K., Miki, Y., Suzuki, T., & Sasano, H. (2013). Androgen receptor in triple negative breast cancer. The Journal of Steroid Biochemistry and Molecular Biology, 133, 66–76. https://doi.org/10.1016/j.jsbmb.2012.08.007
  47. Mei, L., Zhang, Z., Li, X., Yang, Y., & Qi, R. (2023). Metabolomics profiling in prediction of chemo-immunotherapy efficiency in advanced non-small cell lung cancer. Frontiers in Oncology, 12, 1025046. https://doi.org/10.3389/fonc.2022.1025046
  48. Meikle, P. J., Wong, G., Barlow, C. K., & Kingwell, B. A. (2014). Lipidomics: Potential role in risk prediction and therapeutic monitoring for diabetes and cardiovascular disease. Pharmacology & Therapeutics, 143(1), 12–23. https://doi.org/10.1016/j.pharmthera.2014.02.001
  49. Menon, G., Alkabban, F. M., & Ferguson, T. (2025). Breast Cancer. In StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK482286/
  50. Mimmi, M. C., Picotti, P., Corazza, A., Betto, E., Pucillo, C. E., Cesaratto, L., Cedolini, C., Londero, V., Zuiani, C., Bazzocchi, M., & Esposito, G. (2011). High-performance metabolic marker assessment in breast cancer tissue by mass spectrometry. Cclm, 49(2), 317–324. https://doi.org/10.1515/CCLM.2011.060
  51. Miyoshi, Y., Ando, A., Shiba, E., Taguchi, T., Tamaki, Y., & Noguchi, S. (2001). Involvement of up-regulation of 17?-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers. International Journal of Cancer, 94(5), 685–689. https://doi.org/10.1002/ijc.1525
  52. Moore, D.C. PharmD, Bcps, Bcop, Dpla, Fccp, D., & S. Guinigundo, Msn, Rn, Cnp, Anp-Bc, A. (2023). The Role of Biomarkers in Guiding Clinical Decision-Making in Oncology. Journal of the Advanced Practitioner in Oncology, 14(3), 15–37. https://doi.org/10.6004/jadpro.2023.14.3.17
  53. Park, M., Kim, D., Ko, S., Kim, A., Mo, K., & Yoon, H. (2022). Breast Cancer Metastasis: Mechanisms and Therapeutic Implications. International Journal of Molecular Sciences, 23(12), 6806. https://doi.org/10.3390/ijms23126806
  54. Parveen Shaikh, N., Murvanidze, I., Shaikh, A. P., Khurana, R., & Nakashidze, I. (2023). The Altered Gene Expression and Epigenetic Mechanisms in Breast Cancer. Journal of Biomedical Research & Environmental Sciences, 4(10), 1461–1469. https://doi.org/10.37871/jbres1819
  55. Passaro, A., Al Bakir, M., Hamilton, E. G., Diehn, M., André, F., Roy-Chowdhuri, S., Mountzios, G., Wistuba, I. I., Swanton, C., & Peters, S. (2024). Cancer biomarkers: Emerging trends and clinical implications for personalized treatment. Cell, 187(7), 1617–1635. https://doi.org/10.1016/j.cell.2024.02.041
  56. Perou, C. M., Sørlie, T., Eisen, M. B., Van De Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., Fluge, Ø., Pergamenschikov, A., Williams, C., Zhu, S. X., Lønning, P. E., Børresen-Dale, A.-L., Brown, P. O., & Botstein, D. (2000). Molecular portraits of human breast tumours. Nature, 406(6797), 747–752. https://doi.org/10.1038/35021093
  57. Petan, T. (2020). Lipid Droplets in Cancer. In S. H. F. Pedersen & D. L. Barber (Eds.), Organelles in Disease (Vol. 185, pp. 53–86). Springer International Publishing. https://doi.org/10.1007/112_2020_51
  58. Petrović, N., Nakashidze, I., & Nedeljković, M. (2021). Correction to: Breast Cancer Response to Therapy: Can microRNAs Lead the Way? Journal of Mammary Gland Biology and Neoplasia, 26(2), 179–179. https://doi.org/10.1007/s10911-021-09480-9
  59. Petrovic, N., Sami, A., Martinovic, J., Zaric, M., Nakashidze, I., Lukic, S., & Jovanovic-Cupic, S. (2017). TIMP-3 mRNA expression levels positively correlates with levels of miR-21 in in situ BC and negatively in PR positive invasive BC. Pathology - Research and Practice, 213(10), 1264–1270. https://doi.org/10.1016/j.prp.2017.08.012
  60. Possemato, R., Marks, K. M., Shaul, Y. D., Pacold, M. E., Kim, D., Birsoy, K., Sethumadhavan, S., Woo, H.-K., Jang, H. G., Jha, A. K., Chen, W. W., Barrett, F. G., Stransky, N., Tsun, Z.-Y., Cowley, G. S., Barretina, J., Kalaany, N. Y., Hsu, P. P., Ottina, K., Chan, A.M., Yuan, B., Garraway, L.A., Root, D.E., Mino-Kenudson, M., Brachtel, E.F., Driggers, E.M., & Sabatini, D. M. (2011). Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature, 476(7360), 346–350. https://doi.org/10.1038/nature10350
  61. Prat, A., Pineda, E., Adamo, B., Galván, P., Fernández, A., Gaba, L., Díez, M., Viladot, M., Arance, A., & Muñoz, M. (2015). Clinical implications of the intrinsic molecular subtypes of breast cancer. The Breast, 24, S26–S35. https://doi.org/10.1016/j.breast.2015.07.008
  62. Rajkumar, T., Amritha, S., Sridevi, V., Gopal, G., Sabitha, K., Shirley, S., & Swaminathan, R. (2022). Identification and validation of plasma biomarkers for diagnosis of breast cancer in South Asian women. Scientific Reports, 12(1), 100. https://doi.org/10.1038/s41598-021-04176-w
  63. Reis, G. B., Rees, J. C., Ivanova, A. A., Kuklenyik, Z., Drew, N. M., Pirkle, J. L., & Barr, J. R. (2021). Stability of lipids in plasma and serum: Effects of temperature-related storage conditions on the human lipidome. Journal of Mass Spectrometry and Advances in the Clinical Lab, 22, 34–42. https://doi.org/10.1016/j.jmsacl.2021.10.002
  64. Roshanzamir, F., Robinson, J. L., Cook, D., Karimi-Jafari, M. H., & Nielsen, J. (2022). Metastatic triple negative breast cancer adapts its metabolism to destination tissues while retaining key metabolic signatures. Proceedings of the National Academy of Sciences, 119(35), e2205456119. https://doi.org/10.1073/pnas.2205456119
  65. Rossi, C., Cicalini, I., Cufaro, M. C., Consalvo, A., Upadhyaya, P., Sala, G., Antonucci, I., Del Boccio, P., Stuppia, L., & De Laurenzi, V. (2022). Breast cancer in the era of integrating “Omics” approaches. Oncogenesis, 11(1), 17. https://doi.org/10.1038/s41389-022-00393-8
  66. Russo, J., & Russo, I. H. (2006). The role of estrogen in the initiation of breast cancer. The Journal of Steroid Biochemistry and Molecular Biology, 102(1–5), 89–96. https://doi.org/10.1016/j.jsbmb.2006.09.004
  67. Salciccia, S., Capriotti, A. L., Laganà, A., Fais, S., Logozzi, M., De Berardinis, E., Busetto, G. M., Di Pierro, G. B., Ricciuti, G. P., Del Giudice, F., Sciarra, A., Carroll, P. R., Cooperberg, M. R., Sciarra, B., & Maggi, M. (2021). Biomarkers in Prostate Cancer Diagnosis: From Current Knowledge to the Role of Metabolomics and Exosomes. International Journal of Molecular Sciences, 22(9), 4367. https://doi.org/10.3390/ijms22094367
  68. Sánchez-Castillo, A., & Kampen, K. R. (2024). Understanding serine and glycine metabolism in cancer: A path towards precision medicine to improve patient’s outcomes. Discover Oncology, 15(1), 652. https://doi.org/10.1007/s12672-024-01544-6
  69. Schramm, A., De Gregorio, N., Widschwendter, P., Fink, V., & Huober, J. (2015). Targeted Therapies in HER2-Positive Breast Cancer—A Systematic Review. Breast Care, 10(3), 173–178. https://doi.org/10.1159/000431029
  70. Shahisavandi, M., Wang, K., Ghanbari, M., & Ahmadizar, F. (2023). Exploring Metabolomic Patterns in Type 2 Diabetes Mellitus and Response to Glucose-Lowering Medications—Review. Genes, 14(7), 1464. https://doi.org/10.3390/genes14071464
  71. Smolarz, B., Nowak, A. Z., & Romanowicz, H. (2022). Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature). Cancers, 14(10), 2569. https://doi.org/10.3390/cancers14102569
  72. Snell, C. E., Gough, M., Liu, C., Middleton, K., Pyke, C., Shannon, C., Woodward, N., Hickey, T. E., Armes, J. E., & Tilley, W. D. (2018). Improved relapse-free survival on aromatase inhibitors in breast cancer is associated with interaction between oestrogen receptor-α and progesterone receptor-b. British Journal of Cancer, 119(11), 1316–1325. https://doi.org/10.1038/s41416-018-0331-3
  73. Soori, M., Platz, E. A., Brawley, O. W., Lawrence, R. S., & Kanarek, N. F. (2022). Inclusion of the US Preventive Services Task Force Recommendation for Mammography in State Comprehensive Cancer Control Plans in the US. JAMA Network Open, 5(5), e229706. https://doi.org/10.1001/jamanetworkopen.2022.9706
  74. Sun, C., Wang, A., Zhou, Y., Chen, P., Wang, X., Huang, J., Gao, J., Wang, X., Shu, L., Lu, J., Dai, W., Bu, Z., Ji, J., & He, J. (2023). Spatially resolved multi-omics highlights cell-specific metabolic remodeling and interactions in gastric cancer. Nature Communications, 14(1), 2692. https://doi.org/10.1038/s41467-023-38360-5
  75. Suri, G. S., Kaur, G., Carbone, G. M., & Shinde, D. (2023). Metabolomics in oncology. Cancer Reports, 6(3), e1795. https://doi.org/10.1002/cnr2.1795
  76. Suzuki, T., Miki, Y., Moriya, T., Akahira, J., Hirakawa, H., Ohuchi, N., & Sasano, H. (2007). In situ production of sex steroids in human breast carcinoma. Medical Molecular Morphology, 40(3), 121–127. https://doi.org/10.1007/s00795-007-0365-8
  77. Takagi, K., Miki, Y., Nagasaki, S., Hirakawa, H., Onodera, Y., Akahira, J., Ishida, T., Watanabe, M., Kimijima, I., Hayashi, S., Sasano, H., & Suzuki, T. (2010). Increased intratumoral androgens in human breast carcinoma following aromatase inhibitor exemestane treatment. Endocrine-Related Cancer, 17(2), 415–430. https://doi.org/10.1677/ERC-09-0257
  78. Talarico, M. C. R., Derchain, S., Da Silva, L. F., Sforça, M. L., Rocco, S. A., Cardoso, M. R., & Sarian, L. O. (2024). Metabolomic Profiling of Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy for Predicting Disease-Free and Overall Survival. International Journal of Molecular Sciences, 25(16), 8639. https://doi.org/10.3390/ijms25168639
  79. Tan, B., Zhang, Y., Zhang, T., He, J., Luo, X., Bian, X., Wu, J., Zou, C., Wang, Y., & Fu, L. (2020). Identifying potential serum biomarkers of breast cancer through targeted free fatty acid profiles screening based on a GC–MS platform. Biomedical Chromatography, 34(10), e4922. https://doi.org/10.1002/bmc.4922
  80. Tilson-Mallett, N., Santner, S. J., Feil, P. D., & Santen, R. J. (1983). Biological Significance of Aromatase Activity in Human Breast Tumors*. The Journal of Clinical Endocrinology & Metabolism, 57(6), 1125–1128. https://doi.org/10.1210/jcem-57-6-1125
  81. Valko-Rokytovská, M., Očenáš, P., Salayová, A., & Kostecká, Z. (2021). Breast Cancer: Targeting of Steroid Hormones in Cancerogenesis and Diagnostics. International Journal of Molecular Sciences, 22(11), 5878. https://doi.org/10.3390/ijms22115878
  82. Van Den Brandt, P. A., Ziegler, R. G., Wang, M., Hou, T., Li, R., Adami, H.-O., Agnoli, C., Bernstein, L., Buring, J. E., Chen, Y., Connor, A. E., Eliassen, A. H., Genkinger, J. M., Gierach, G., Giles, G. G., Goodman, G. G., Håkansson, N., Krogh, V., Le Marchand, L., Lee, I.M., Liao, L.M., Martinez, M.E., Miller, A.B., Milne, R.L., Neuhouser, M.L., Patel, A.V., Prizment, A., Robien, K., Rohan, T.E., Sawada, N., Schouten, L.J., Sinha, R., Stolzenberg-Solomon, R.Z., Teras, L.R., Tsugane, S., Visvanathan, K., Weiderpass, E., White, K.K., Willett, W.C., Wolk, A., Zeleniuch-Jacquotte, A., & Smith-Warner, S. A. (2021). Body size and weight change over adulthood and risk of breast cancer by menopausal and hormone receptor status: A pooled analysis of 20 prospective cohort studies. European Journal of Epidemiology, 36(1), 37–55. https://doi.org/10.1007/s10654-020-00688-3
  83. Veerla, S., Hohmann, L., Nacer, D. F., Vallon-Christersson, J., & Staaf, J. (2023). Perturbation and stability of PAM50 subtyping in population-based primary invasive breast cancer. Npj Breast Cancer, 9(1), 83. https://doi.org/10.1038/s41523-023-00589-0
  84. Vinogradova, Y., Coupland, C., & Hippisley-Cox, J. (2020). Use of hormone replacement therapy and risk of breast cancer: Nested case-control studies using the QResearch and CPRD databases. BMJ, m3873. https://doi.org/10.1136/bmj.m3873
  85. Wagner-Golbs, A., Neuber, S., Kamlage, B., Christiansen, N., Bethan, B., Rennefahrt, U., Schatz, P., & Lind, L. (2019). Effects of Long-Term Storage at −80 °C on the Human Plasma Metabolome. Metabolites, 9(5), 99. https://doi.org/10.3390/metabo9050099
  86. Yang, K., & Han, X. (2016). Lipidomics: Techniques, Applications, and Outcomes Related to Biomedical Sciences. Trends in Biochemical Sciences, 41(11), 954–969. https://doi.org/10.1016/j.tibs.2016.08.010